💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Avelumab

CHEMBL3833373 Phase 4 Đã phê duyệt Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A PD-L1 checkpoint inhibitor that blocks PD-L1 expressed on tumor cells from binding to PD-1 on T cells, unleashing an immune attack against the cancer. It is approved for Merkel cell carcinoma and urothelial carcinoma.

Lĩnh vực điều trị

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Melanoma Oncology Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Cơ chế tác dụng

Blocks immune checkpoint proteins (PD-1, PD-L1, or CTLA-4) that normally suppress T-cell activation, thereby releasing the brakes on the anti-tumor immune response. This allows cytotoxic T lymphocytes to recognize and destroy cancer cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Blocks immune checkpoint proteins (PD-1, PD-L1, or CTLA-4) that normally suppress T-cell activation, thereby releasing the brakes on the anti-tumor immune response. This allows cytotoxic T lymphocytes to recognize and …

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A PD-L1 checkpoint inhibitor that blocks PD-L1 expressed on tumor cells from binding to PD-1 on T cells, unleashing an immune attack against the cancer. It is approved for Merkel cell carcinoma and urothelial carcinoma.

Blocks immune checkpoint proteins (PD-1, PD-L1, or CTLA-4) that normally suppress T-cell activation, thereby releasing the brakes on the anti-tumor immune response. This allows cytotoxic T lymphocytes to recognize and destroy cancer cells.

Yes, Avelumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3833373. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.